C4 Therapeutics to Participate in Upcoming Conferences

C4 Therapeutics (Nasdaq: CCCC) announced management participation in several upcoming healthcare and oncology conferences.

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) announced management participation in several upcoming healthcare and oncology conferences. Events include TD Cowen’s 7th Annual Oncology Innovation Summit on May 26, 2026, the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026.

Fireside chats and 1x1 meetings will be held virtually and in person, with live webcasts and 90‑day archived replays accessible via the company’s investor relations website.

Argus May 20 session

+5.47% close to close Open Argus

Details

News Market Reaction – CCCC

In the May 20 session, CCCC gained 5.47%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +5.5% in the session following this news. A strong positive reaction aligns with the company’s strategy of increasing institutional visibility through high-profile healthcare conferences. Past news on collaborations and trial progress produced moves that generally tracked the tone of announcements. However, the existence of an effective capital-raising framework of up to $400,000,000 and prior equity financing means investors would need to weigh potential future issuance alongside enthusiasm for increased exposure.

Key Figures

TD Cowen summit time: May 26, 2026, 2:30 pm ET Jefferies conference time: June 3, 2026, 8:45 am ET Goldman Sachs meetings date: June 10, 2026 +1 more

TD Cowen summit time

May 26, 2026, 2:30 pm ET

TD Cowen 7th Annual Oncology Innovation Summit fireside chat

Jefferies conference time

June 3, 2026, 8:45 am ET

2026 Jefferies Global Healthcare Conference fireside chat

Goldman Sachs meetings date

June 10, 2026

Goldman Sachs 47th Annual Global Healthcare Conference 1x1 meetings

Webcast archive period

90 days

Archived replays of conference webcasts

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Q1 2026 earnings

   24h Move

   +0.0%

   Reported lower revenue and net loss with solid cash runway and pipeline progress.

2. Apr 09

   Roche collaboration

   24h Move

   -2.4%

   Expanded Roche partnership with $20M upfront and over $1B potential milestones.

3. Mar 25

   Phase 1b trial start

   24h Move

   +7.6%

   First patient dosed in Phase 1b cemsidomide plus elranatamab multiple myeloma study.

4. Mar 09

   Inducement option grant

   24h Move

   -13.1%

   Announced non-qualified stock option grant to a new employee under Nasdaq rules.

5. Feb 26

   FY 2025 earnings

   24h Move

   +0.4%

   Reported 2025 results, cash runway to end of 2028, and cemsidomide Phase 2 progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

targeted protein degradation

1 terms

targeted protein degradation medical

"a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences.

TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

• Management will participate in a virtual fireside chat on May 26, 2026, at 2:30 pm ET.
  
  

2026 Jefferies Global Healthcare Conference

• Management will participate in a fireside chat on June 3, 2026, at 8:45 am ET, taking place in New York, New York.
  
  

Goldman Sachs 47th Annual Global Healthcare Conference

• Management will participate in 1x1 meetings on June 10, 2026, taking place in Miami, FL.
  
  

The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com. Archived replays of the webcasts will be available for approximately 90 days following the events.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com

Leah Gibson
Vice President, Investor Relations & Communications
LGibson@c4therapeutics.com

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will C4 Therapeutics (NASDAQ: CCCC) present at the TD Cowen 7th Annual Oncology Innovation Summit?

C4 Therapeutics management will join a virtual fireside chat on May 26, 2026, at 2:30 p.m. ET. According to the company, investors can access a live webcast via its investor relations website.

What is the schedule for C4 Therapeutics at the 2026 Jefferies Global Healthcare Conference?

C4 Therapeutics management will participate in a fireside chat on June 3, 2026, at 8:45 a.m. ET in New York. According to the company, the session will be webcast live for investors.

How is C4 Therapeutics involved in the Goldman Sachs 47th Annual Global Healthcare Conference 2026?

C4 Therapeutics management will take part in 1x1 investor meetings on June 10, 2026, in Miami, Florida. According to the company, these meetings aim to engage with institutional investors and analysts.

Where can investors watch the C4 Therapeutics (CCCC) conference webcasts?

Investors can access live webcasts in the Investors section of the C4 Therapeutics website at www.c4therapeutics.com. According to the company, the interface will host multiple upcoming conference events.

How long will C4 Therapeutics’ conference webcasts and replays be available to investors?

Archived replays of C4 Therapeutics’ conference webcasts will be available for about 90 days after each event. According to the company, this allows investors to review presentations at their convenience.

What types of investor interactions will C4 Therapeutics offer during its May–June 2026 conferences?

C4 Therapeutics will host virtual fireside chats, an in-person fireside chat, and 1x1 meetings. According to the company, these formats support detailed discussion of its targeted protein degradation pipeline.